Clinical aspects of melatonin in the acute coronary syndrome

Current Vascular Pharmacology

Volumn 7, Issue 3, 2009, Pages 367-373

  Dominguez Rodriguez, Alberto ^a   Abreu Gonzalez, Pedro ^b   Reiter, Russel J ^c  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

^c Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Acute coronary syndrome; Atherosclerosis; Coronary artery disease; Diurnal variations; Inflammation; Ischemia reperfusion; Melatonin

Indexed keywords

FREE RADICAL; MELATONIN; MELATONIN RECEPTOR;

ACUTE CORONARY SYNDROME; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; BINDING SITE; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CELL DAMAGE; CIRCADIAN RHYTHM; CLINICAL TRIAL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART OUTPUT; HEART RATE; HORMONE SYNTHESIS; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; ISCHEMIC HEART DISEASE; NONHUMAN; REVIEW; SEASONAL VARIATION; SUDDEN DEATH; SUPRACHIASMATIC NUCLEUS; VASCULAR DISEASE; VASOCONSTRICTION; VASODILATATION; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; CORONARY ARTERY DISEASE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REPERFUSION INJURY;

ACUTE CORONARY SYNDROME; ANIMALS; CARDIOVASCULAR SYSTEM; CORONARY ARTERY DISEASE; HUMANS; MELATONIN; MODELS, BIOLOGICAL; MYOCARDIAL REPERFUSION INJURY; SUPRACHIASMATIC NUCLEUS;

EID: 69149109844     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016109788340749     Document Type: Review

References (109)

1. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436-42.
2. Hansson GK. Mechanisms of disease inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
3. Garcia-Moll X. Inflammatory and anti-inflammatory markers in acute coronary syndromes. Ready for use in the clinical setting? Rev Esp Cardiol 2005; 58: 615-7.
4. Angiolillo DJ, Biasucci LM, Liuzzo G, Crea F. Inflammation in acute coronary syndromes: mechanisms and clinical implications. Rev Esp Cardiol 2004; 57: 433-46.
5. Muller JE, Tofler GH. Circadian variation and cardiovascular disease. N Engl J Med 1991; 325: 1038-9.
6. Willich SN, Goldberg RJ, Maclure M, Perriello L, Muller JE. Increased onset of sudden cardiac death in the first three hours after awakening. Am J Cardiol 1992; 70: 65-8.
7. Reilly DF, Westgate EJ, FitzGerald GA. Peripheral circadian clocks in the vasculature. Arterioscler Thromb Vasc Biol 2007; 27: 1694-705.
8. Rajaratnam SM, Arendt J. Health in a 24-h society. Lancet 2001; 358: 999-1005.
9. Knutsson A. Health disorders of shift workers. Occup Med (Lond) 2003; 53: 103-8.
10. Tengattini S, Reiter RJ, Tan DX, Terron MP, Rodella LF, Rezzani R. Cardiovascular diseases: protective effects of melatonin. J Pineal Res 2008; 44: 16-25.
11. Simko F, Paulis L. Melatonin as a potential antihypertensive treatment. J Pineal Res 2007; 42: 319-22.
12. Lemmer B. Circadian rhythms in the cardiovascular system. In: Arendt J, Minors DS, Waterhouse JM, editors. Biological rhythms in clinical practice. Boston: Butterworths Eds. 1989; 51-70.
13. Sewerynek E. Melatonin and the cardiovascular system. Neuroendocrinol lett 2002; 23: 79-83.
14. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991; 12: 151-80.
15. Korf HW, Von Gall C, Stehle J. The circadian system and melatonin: lessons from rats and mice. Chronobiol Int 2003; 20: 697-710.
16. Reiter RJ. Melatonin: the chemical expression of darkness. Mol Cell Endocrinol 1991; 79: C153-8.
17. Foulkes NS, Whitmore D, Sassone-Corsi P. Rhythmic transcription: the molecular basis of circadian melatonin synthesis. Biol Cell 1997; 89: 487-94.
18. Karolczak M, Korf HW, Stehle JH. The rhythm and blues of gene expression in the rodent pineal gland. Endocrine 2005; 27: 89-100.
19. Reiter RJ. The melatonin rhythm: both a clock and a calendar. Experientia 1993; 49: 654-64.
20. Lane EA, Moss HB. Pharmacokinetics of melatonin in man: first pass hepatic metabolism. J Clin Endocrinol Metab 1985; 61: 1214-6.
21. Sharma M, Palacios Bois J, Schwartz G, Iskandar H, Thakur M, Quirion R, et al. Circadian rhythms of melatonin and cortisol in aging. Biol Psychiatry 1989; 25: 305-19.
22. Bubenik GA. Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci 2002; 47: 2336-48.
23. Witt-Enderby PA, Radio NM, Doctor JS, Davis VL. Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy. J Pineal Res 2006; 41:297-305.
24. Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005; 27:101-10.
25. Pang CS, Xi SC, Brown GM, Pang SF, Shiu SY. 2[125I]Iodomelatonin binding and interaction with beta-adrenergic signaling in chick heart/coronary artery physiology. J Pineal Res 2002; 32: 243-52.
26. Ekmekcioglu C, Thalhammer T, Humpeler S, Mehrabi MR, Glogar HD, Holzenbein T, et al. The melatonin receptor subtype MT2 is present in the human cardiovascular system. J Pineal Res 2003; 35: 40-4.
27. Ekmekcioglu C, Haslmayer P, Philipp C, Mehrabi MR, Glogar HD, Grimm M, et al. 24h variation in the expression of the mt1 melatonin receptor subtype in coronary arteries derived from patients with coronary heart disease. Chronobiol Int 2001; 18: 973-85.
28. Abete P, Bianco S, Calabrese C, Napoli C, Cacciatore F, Ferrara N, et al. Effects of melatonin in isolated rat papillary muscle. FEBS Lett 1997; 412: 79-85.
29. Ekmekcioglu C, Haslmayer P, Philipp C, Mehrabi MR, Glogar HD, Grimm M, et al. Expression of the MT1 melatonin receptor subtype in human coronary arteries. J Recept Signal Transduct Res 2001; 21: 85-91.
30. Yang Q, Scalbert E, Delagrange P, Vanhoutte PM, O'Rourke ST. Melatonin potentiates contractile responses to serotonin in isolated porcine coronary arteries. Am J Physiol Heart Circ Physiol 2001; 280: H76-82.
31. Masana MI, Doolen S, Ersahin C, Al-Ghoul WM, Duckles SP, Dubocovich ML, et al. MT(2) melatonin receptors are present and functional in rat caudal artery. J Pharmacol Exp Ther 2002; 302: 1295-302.
32. Ekmekcioglu C. Melatonin receptors in humans: biological role and clinical relevance. Biomed Pharmacother 2006; 60: 97-108.
33. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 2007; 27: 15-26.
34. Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 2003; 41: 15S-22S.
35. Landmesser U, Harrison DG. Oxidant stress as marker for cardiovascular events: Ox marks the spot. Circulation 2001; 104: 2638-40.
36. Witztum JL, Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc Med 2001; 11: 93-102.
37. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-24.
38. Allegra M, Reiter RJ, Tan DX, Gentile C, Tesoriere L, Livrea MA. The chemistry of melatonin's interaction with reactive species. J Pineal Res 2003; 34:1-10.
39. Hardeland R. Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine 2005; 27: 119-30.
40. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007; 42: 28-42.
41. Pieri C, Marra M, Gaspar R, Damjanovich S. Melatonin protects LDL from oxidation but does not prevent the apolipoprotein derivatization. Biochem Biophys Res Commun 1996; 222: 256-60.
42. Kelly MR, Loo G. Melatonin inhibits oxidative modification of human low-density lipoprotein. J Pineal Res 1997; 22: 203-9.
43. Seegar H, Mueck AO, Lippert TH. Effect of melatonin and metabolites on cooper-mediated oxidation of low density lipoprotein. Br J Clin Pharmacol 1997; 44: 283-4.
44. Hoyos M, Guerrero JM, Perez-Cano R, Olivan J, Fabiani F, Garcia-Perganeda A, et al. Serum colesterol and lipid peroxidation are decreased by melatonin in diet-induced hypercholesterolemic rats. J Pineal Res 2000; 28: 150-5.
45. Abyja PM, Liebman P, Hayn M, Schauenstein K, Esterbauer H. Antioxidant role of melatonin in lipid peroxidation of human LDL. FEBS Lett 1997; 413: 289-93.
46. Wakatsuki A, Okatani Y, Ikenoue N, Shinohara K, Watanabe K, Fukaya T. Melatonin protects against oxidized low-density lipoprotein-induced inhibition of nitric oxide production in human umbilical artery. J Pineal Res 2001; 31: 281-8.
47. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez M, Ferrer-Hita J, Vargas M, Reiter RJ. Elevated levels of oxidized low-density lipoprotein and impaired nocturnal synthesis of melatonin in patients with myocardial infarction. Atherosclerosis 2005; 180: 101-5.
48. Tamura H, Nakamura Y, Narimatsu A, Yamagata Y, Takasaki A, Reiter RJ, et al. Melatonin treatment in peri- and postmenopausal women elevates serum high-density lipoprotein cholesterol levels without influencing total cholesterol levels. J Pineal Res 2008; 45: 101-5.
49. Reiter RJ. Melatonin: Lowering the high price of free radicals. News Physiol Sci 2000; 15: 246-50.
50. Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes: part II: acute-phase reactants and biomarkers of endothelial cell activation. Circulation 2006; 113: e152-5.
51. Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003; 108: 1930-2.
52. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001; 158: 1039-51.
53. Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the múltiple actions of melatonin on the immune system. Endocrine 2005; 27: 189-200.
54. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia M, Ferrer J, de la Rosa A, Vargas M, et al. Light/dark patterns of interleukin-6 in relation to the pineal hormone melatonin in patients with acute myocardial infarction. Cytokine 2004; 26: 89-93.
55. Dominguez-Rodriguez A, Garcia-Gonzalez M, Abreu-Gonzalez P, Ferrer J, Kaski JC. Relation of nocturnal melatonin levels to C-reactive protein concentration in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2006; 97: 10-2.
56. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Reiter RJ. Relation of nocturnal melatonin levels to serum matriz metalloproteinase-9 concentrations in patients with myocardial infarction. Thromb Res 2007; 120: 361-6.
57. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Samimi-Fard S, Kaski JC, Reiter RJ. Light/dark patterns of soluble vascular cell adhesión molecule-1 in relation to melatonin in patients with ST-segment elevation myocardial infarction. J Pineal Res 2008; 44: 65-9.
58. Reiter RJ, Calvo JR, Karbownik M, Qi W, Tan DX. Melatonin and its relation to the immune system and inflammation. Ann N Y Acad Sci 2000; 917: 376-86.
59. Sewerynek E, Reiter RJ, Melchiorri D, Ortriz GG, Lewinski A. Oxidative damage in the liver induced by ischemia-reperfusion: protection by melatonin. Hepatogastroenterology 1996; 43: 898-905.
60. Sener G, Tugtepe H, Velioglu-Ogunc A, Cetinel S, Gedik N, Yegen BC. Melatonin prevents neutrophil-mediated oxidative injury in Escherichia coli-induced pyelonephritis in rats. J Pineal Res 2006; 41: 220-7.
61. Mazzon E, Esposito E, Crisafulli C, Riccardi L, Muia C, Di Bella P, et al. Melatonin modulates signal transduction pathways and apoptosis in experimental colitis. J Pineal Res 2006; 41: 363-73.
62. Apple FS, Wu AH, Mair J, Ravkilde J, Panteghini M, Tate J, et al. Committee on Standardization of Markers of Cardiac Damage of the IFCC. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005; 51: 810-24.
63. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez M, Reiter RJ. Prognostic value of nocturnal melatonin levels as a novel marker in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2006; 97: 1162-4.
64. Antman EM, Ande DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). Circulation 2004; 110: 588-636.
65. Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction and improved survival. Should the paradigm be expanded? Circulation 1989; 79: 441-4.
66. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1,000 patients. Lancet 1994; 343: 311-22.
67. GUSTO IIb Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997; 336: 1621-8.
68. Moens AL, Claeys MJ, Timmermans JP, Vrints CJ. Myocardial ischemia/ reperfusion-injury, a clinical view on a complex pathophysiological process. Int J Cardiol 2005; 100: 179-90.
69. Zweier JL. Measurement of superoxide-derived free radicals in the reperfused heart. Evidence for a free radical mechanism of reperfusion injury. J Biol Chem 1988; 263: 1353-7.
70. Robert L, Engler MD. Free radical and granulocyte-mediated injury during myocardial ischemia and reperfusion. Am J Cardiol 1989; 63: E19-23.
71. Beard T, Carrie D, Boyer MJ, Boudjemaa B, Ferrieres J, Delay M, et al. Production of oxygen free radicals in myocardial infarction treated by thrombolysis. Analysis of glutathione peroxidase, superoxide dismutase and malondialdehyde. Arch Mal Coeur Vaiss 1994; 87: 1289-96.
72. Roberts MJ, Young IS, Trouton TG, Trimble ER, Khan MM, Webb SW, et al. Transient release of lipid peroxides after coronary artery balloon angioplasty. Lancet 1990; 336: 143-5.
73. Kim KB, Chung HH, Kim MS, Rho JR. Changes in the antioxidative defensive system during open heart operations in humans. Ann Thorac Surg 1994; 58: 170-5.
74. Reiter RJ, Tan DX, Gitto E, Sainz RM, Mayo JC, Leon J, et al. Pharmacological utility of melatonin in reducig oxidative cellular and molecular damge. Pol J Pharmacol 2004; 56: 159-70.
75. Salie R, Harper I, Cillie C, Genade S, Huisamen B, Moolman J, et al. Melatonin protects against ischaemic-reperfusion myocardial damage. J Mol Cell Cardiol 2001; 33: 343-57.
76. Tan DX, Manchester LC, Reiter RJ, Qi W, Kim SJ, El-sokkary GH. Ischemia/ reperfusion-induced arrhythmias in the isolated rat heart: prevention by melatonin. J Pineal Res 1998; 25: 184-91.
77. Kaneko S, Okumura K, Numaguchi Y, Matsui H, Murase K, Mokuno S, et al. Melatonin scavenges hydroxyl radical and protects isolated rat hearts from ischemic reperfusion injury. Life Sci 2000; 67: 101-12.
78. Lagneux C, Joyeux M, Demenge P, Ribuot C, Godin-Ribuot D. Protective effects of melatonin against ischemia-reperfusion injury in the isolated rat heart. Life Sci 2000; 66: 503-9.
79. Szarszoi O, Asemu G, Vanecek J, Ost'adal B, Kolar F. Effects of melatonin on ischemia and reperfusion injury of the rat heart. Cardiovasc Drugs Ther 2001; 15: 251-7.
80. Lee YM, Chen HR, Hsiao G, Sheu JR, Wang JJ, Yen MH. Protective effects of melatonin on myocardial ischemia/reperfusion injury in vivo. J Pineal Res 2002; 33: 72-80.
81. Sahna E, Olmez E, Acet A. Effects of physiological and pharmacological concentrations of melatonin on ischemia-reperfusion arrhythmias in rats: can the incidence of sudden cardiac death be reduced? J Pineal Res 2002; 32: 194-8.
82. Sahna E, Parlakpinar H, Ozer MK, Ozturk F, Ozugurlu F, Acet A. Melatonin protects against myocardial doxorubicin toxicity in rats: role of physiological concentrations. J Pineal Res 2003; 35: 257-61.
83. Sahna E, Parlakpinar H, Turkoz Y, Acet A. Protective effects of melatonin on myocardial ischemia/reperfusion induced infarct size and oxidative damage. Physiol Res 2005; 54: 491-5.
84. Chen Z, Chua CC, Gao J, Hamdy RC, Chua BH. Protective effect of melatonin on myocardial infarction. Am J Physiol 2003; 284: H1618-24.
85. Lee YM, Chen HR, Hsiao G, Sheu JR, Wang JJ, Yen MH. Protective effect of melatonin on myocardial ischemia/reperfusion injury in vivo. J Pineal Res 2002; 33: 72-80.
86. Tomas-Zapico C, Coto-Montes A. A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. J Pineal Res 2005; 39: 99-104.
87. Lochner A, Genade S, Davids A, Ytrehus K, Moolman JA. Short-and long-term effects of melatonin on myocardial post-ischemic recovery. J Pineal Res 2006; 40: 56-63.
88. Salline P, Manttari S, Leskinen H, Ilves M, Vakkuri O, Ruskoaho H, et al. The effect of myocardial infarction on the synthesis, concentration and receptor expression of endogenous melatonin. J Pineal Res 2007; 42: 254-60.
89. +2 binding amino-acid residues of the N-terminus of human albumin: an insight into the mechanism of a new assay for myocardial ischemia. Eur J Biochem 2001; 268: 42-7.
90. Roy D, Quiles J, Gaze DC, Collinson P, Kaski JC, Baxter GF. Role of reactive oxygen species on the formation of the novel diagnostic marker ischemia modified albumin. Heart 2006; 92: 113-4.
91. Poeggeler B, Saarela S, Reiter RJ, Tan DX, Chen LD, Manchester LC, et al. Melatonin - a highly potent endogenous radical scavenger and electron donor: new aspects of the oxidation chemistry of this indole accessed in vitro. Ann N Y Acad Sci. 1994; 738: 419-20.
92. Reiter RJ, Tan DX. Melatonin: a novel protective agent against oxidative injury of the ischemic/reperfused heart. Cardiovasc Res 2003; 58: 10-9.
93. Tan DX, Manchester LC, Burkhardt S, Sainz RM, Mayo JC, Kohen R, et al. N1-acetyl-N2-formyl-5-methoxykynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant. FASEB J 2001; 15: 2294-6.
94. León J, Escames G, Rodríguez MI, López LC, Tapias V, Entrena A, et al. Inhibition of neuronal nitric oxide synthase activity by N1-acetyl-5-methoxykynuramine, a brain metabolite of melatonin. J Neurochem 2006; 98: 2023-33.
95. +, *NO and HNO (protonated NO-) with the melatonin metabolite N1-acetyl-5- methoxykynuramine. J Pineal Res 2007; 43: 382-8.
96. Brugger P, Marktl W, Herold M. Impaired nocturnal secretion of melatonin in coronary artery dissease. Lancet 1995; 345: 1408.
97. Brugger P, Herold M. Human melatonin and cortisol circadian rhythms in patients with coronary heart disease. Biol Rhythm Res 1998; 29: 121-8.
98. Sakotnik A, Liebmann PM, Stoschitsky K, Lercher P, Schauenstein K, Klein W, et al. Decreased melatonin synthesis in patients with coronary artery disease. Eur Heart J 1999; 20: 1314-7.
99. Altun A, Yaprak M, Aktoz M, Vardar A, Betul UA, Ozbay G. Impaired nocturnal synthesis of melatonin in patients with cardiac syndrome X. Neurosci Lett 2002; 327: 143-5.
100. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia M, Sanchez J, Marrero F, de Armas Trujillo D. Decreased nocturnal melatonin levels during acute myocardial infarction. J Pineal Res 2002; 33: 248-52.
101. Dobsak P, Siegelova J, Eicher JC, Jancik J, Svacinova H, Vasku J, et al. Melatonin protects against ischemia-reperfusion injury and inhibits apoptosis in isolated working rat heart. Pathophysiology 2003; 9: 179-87.
102. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Samimi-Fard S, Reiter RJ, Kaski JC. Association of ischemiamodified albumin and melatonin in patients with ST-elevation myocardial infarction. Atherosclerosis 2007; 199: 73-8.
103. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Kaski JC, Reiter RJ. The melatonin adjunct in the acute myocardial infarction treated with primary angioplasty: study design and rationale (MARIA TRIAL). Atherosclerosis 2006; 7 (Suppl 3): 122.
104. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Kaski JC, Reiter RJ, Jimenez-Sosa A. A unicenter, randomized, double-blind, parallel-group, placebo-controlled study of Melatonin as an Adjunct in patients with acute myocaRdial Infarction undergoing primary Angioplasty. The Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty (MARIA) trial: study design and rationale. Contemp Clin Trials 2007; 28: 532-9.
105. Seabra ML, Bignotto M, Pinto LR Jr, Tufik S. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J Pineal Res 2000; 29: 193-200.
106. Gitto E, Reiter RJ, Amodio A, Romeo C, Cuzzocrea E, Sabatino G, et al. Early indicators of chronic lung disease in preterm infant with respiratory distress syndrome and their inhibition by melatonin. J Pineal Res 2004; 36: 250-5.
107. Kücükakin B, Lykkesfeldt J, Nielsen HJ, Reiter RJ, Rosenberg J, Gögenur I. Utility of melatonin to treat surgical after major vascular surgery-a safety study. J Pineal Res 2008; 44: 426-31.
108. Gitto E, Karbownik M, Reiter RJ, Tan DX, Cuzzocrea S, Chiurazzi P, et al. Effects of melatonin treatment in septic newborns. Pediatr Res 2001; 50: 756-60.
109. Gitto E, Romeo C, Reiter RJ, Impellizzeri P, Pesce S, Basile M, et al. Melatonin reduces oxidative stress in surgical neonates. J Pediatr Surg 2004; 39: 184-9.